La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Ensysce Biosciences Gestion

Gestion contrôle des critères 4/4

Le PDG Ensysce Biosciences' est D. Kirkpatrick, nommé en Jan2009, a un mandat de 15.58 ans. La rémunération annuelle totale est $ 508.58K, composée du salaire de 79.6% et des bonus 20.4%, y compris les actions et options de la société. détient directement 0.021% des actions de la société, d'une valeur de $ 636.55. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 4.7 ans et 4 ans.

Informations clés

D. Kirkpatrick

Directeur général

US$508.6k

Rémunération totale

Pourcentage du salaire du PDG	79.6%
Durée du mandat du directeur général	15.6yrs
Propriété du PDG	0.02%
Durée moyenne d'occupation des postes de direction	4.7yrs
Durée moyenne du mandat des membres du conseil d'administration	4yrs

Mises à jour récentes de la gestion

Recent updates

Ensysce Biosciences secures $8M convertible note financing

Jul 01

Ensysce Biosciences: Developing New Class Of Tamper-Proof Powerful Opioids

Dec 18

Analyse de la rémunération des PDG

Comment la rémunération de D. Kirkpatrick a-t-elle évolué par rapport aux bénéfices de Ensysce Biosciences?
Date	Rémunération totale	Salaire	Bénéfices de l'entreprise
Jun 30 2024	n/a	n/a	-US$11m
Mar 31 2024	n/a	n/a	-US$12m
Dec 31 2023	US$509k	US$405k	-US$11m
Sep 30 2023	n/a	n/a	-US$13m
Jun 30 2023	n/a	n/a	-US$20m
Mar 31 2023	n/a	n/a	-US$26m
Dec 31 2022	US$623k	US$393k	-US$25m
Sep 30 2022	n/a	n/a	-US$30m
Jun 30 2022	n/a	n/a	-US$38m
Mar 31 2022	n/a	n/a	-US$31m
Dec 31 2021	US$288k	US$174k	-US$30m
Sep 30 2021	n/a	n/a	-US$19m
Jun 30 2021	n/a	n/a	-US$99k
Mar 31 2021	n/a	n/a	US$172k
Dec 31 2020	US$156k	US$156k	US$57k

Rémunération vs marché: La rémunération totale de D. ($USD 508.58K ) est dans la moyenne des entreprises de taille similaire sur le marché US ($USD 681.57K ).

Rémunération et revenus: La rémunération de D. a été cohérente avec les performances de l'entreprise au cours de l'année écoulée.

PDG

D. Kirkpatrick (67 yo)

15.6yrs

Titularisation

US$508,575

Compensation

Dr. D. Lynn Kirkpatrick, Ph.D. is a Co Founder of ProlX Pharmaceuticals Corporation and has been its Chief Executive Officer since 1999. She has been Chief Executive Officer of Ensysce Biosciences, Inc. si...

Équipe de direction

Nom	Position	Titularisation	Compensation	Propriété
D. Kirkpatrick	President	15.6yrs	US$508.58k	0.021% $ 724.2
David Humphrey	CFO, Secretary & Treasurer	3.5yrs	US$441.95k	0.0027% $ 94.6
Geoffrey Birkett	Chief Commercial Officer	5.8yrs	US$392.35k	0% $ 0
Jeffrey Millard	Chief Operating Officer	less than a year	pas de données	pas de données
William Schmidt	Chairman of Clinical Advisory Board & Chief Medical Officer	8.6yrs	pas de données	pas de données
Linda Pestano	Chief Development Officer	2.8yrs	pas de données	0% $ 0

4.7yrs

Durée moyenne de l'emploi

58yo

Âge moyen

Gestion expérimentée: L'équipe de direction de ENSC est considérée comme expérimentée (ancienneté moyenne 4.7 ans).

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
D. Kirkpatrick	President	7.3yrs	US$508.58k	0.021% $ 724.2
William Schmidt	Chairman of Clinical Advisory Board & Chief Medical Officer	1.9yrs	pas de données	pas de données
Robert Gower	Independent Chairman of the Board	16.6yrs	US$47.60k	1.61% $ 55.5k
Lee Rauch	Independent Director	2.5yrs	US$29.17k	0% $ 0
Andrew Benton	Independent Director	4.7yrs	US$30.10k	0.26% $ 9.1k
Richard Dart	Member of the Clinical Advisory Board	no data	pas de données	pas de données
Steven Martin	Independent Director	4yrs	US$32.92k	0% $ 0
Lynn Webster	Member of the Clinical Advisory Board	no data	pas de données	pas de données
Hui-Chung Chang	Independent Director	8.6yrs	US$30.10k	0.41% $ 14.2k
Jeffrey Gudin	Member of the Clinical Advisory Board	no data	pas de données	pas de données
Curtis Rosebraugh	Independent Director	3.2yrs	US$25.42k	0% $ 0
Adam Levin	Independent Director	3.2yrs	US$27.92k	0% $ 0

4.0yrs

Durée moyenne de l'emploi

67.5yo

Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de ENSC sont considérés comme expérimentés (ancienneté moyenne 4 ans).

Ensysce Biosciences Gestion

Gestion contrôle des critères 4/4

Informations clés

Mises à jour récentes de la gestion

Ensysce Biosciences, Inc., Annual General Meeting, Aug 24, 2023

Independent Chairman of the Board recently bought US$182k worth of stock

High number of new directors

Ensysce Biosciences, Inc. Announces Chief Medical Officer Changes

Independent Chairman of the Board notifies of intention to sell stock

Ensysce Biosciences, Inc. Appoints William Chang as Director

Recent updates

Consensus revenue estimates decrease by 25%, EPS upgraded

Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Consensus revenue estimates decrease by 26%, EPS upgraded

No longer forecast to breakeven

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target increased by 16% to US$13.50

Ensysce Biosciences Receives Notice from The Nasdaq Stock Market Regarding Non-Compliance with Nasdaq Listing Rule 5550(a)(2)

Consensus EPS estimates fall by 32%

Price target decreased by 16% to US$11.33

Forecast to breakeven in 2026

Full year 2023 earnings released

Price target decreased by 13% to US$11.65

Ensysce Biosciences Announces Publication of Clinical Bioequivalence Manuscript

New minor risk - Profitability

Price target decreased by 13% to US$11.65

Ensysce Biosciences Announces Positive End of Phase 2 Meeting with FDA for PF614 to Treat Severe Pain

Ensysce Biosciences, Inc. has filed a Follow-on Equity Offering.

Ensysce Biosciences, Inc. Announces Key Efficacy Data for Lead Analgesic

New major risk - Share price stability

Ensysce Biosciences, Inc. announced that it has received $1.7 million in funding

Ensysce Biosciences Receives Non-Compliance Notice from Nasdaq

Ensysce Biosciences, Inc. Announces Enrollment Completion for PF614-201 Clinical Study

Consensus revenue estimates decrease by 21%, EPS upgraded

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Ensysce Biosciences, Inc. announced that it expects to receive $1.7 million in funding

Ensysce Biosciences, Inc. Announces Completion of Site Initiation Visit for PF614-201 Clinical Study

Ensysce Biosciences Completes Scale Up Manufacture of PF614 to Support Phase 3 Studies

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Ensysce Biosciences, Inc. Announces Investigational Review Board Approval of Key Study Protocol

Ensysce Biosciences, Inc., Annual General Meeting, Aug 24, 2023

Ensysce Biosciences Regains Compliance with the Equity Requirement in Nasdaq Listing Rule 5550(b)(1)

Consensus EPS estimates upgraded to US$9.75 loss, revenue downgraded

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Ensysce Biosciences, Inc. has completed a Follow-on Equity Offering.

Consensus revenue estimates increase by 14%

Price target decreased by 58% to US$29.40

Full year 2022 earnings: EPS and revenues miss analyst expectations

Independent Chairman of the Board recently bought US$182k worth of stock

Ensysce Biosciences, Inc. has completed a Follow-on Equity Offering in the amount of $3.000002 million.

Ensysce Biosciences Receives Non-Compliance Notice from Nasdaq

Ensysce Biosciences, Inc. Announces Initiation of Final Stage of Groundbreaking Opioid Overdose Protection Phase 1 Study

Ensysce Biosciences, Inc. Announces Successful Completion of Clinical Portion of Oral Human Abuse Potential Trial

Ensysce Biosciences Announces Data from PF614-MPAR-101-Part A Successfully Demonstrating Opioid Overdose Protection

Ensysce Biosciences Receives Non-Compliance Notice from Nasdaq

Consensus forecasts updated

Ensysce Biosciences, Inc. has completed a Follow-on Equity Offering in the amount of $4.06 million.

Ensysce Biosciences, Inc. has completed a Follow-on Equity Offering in the amount of $4.06 million.

Ensysce Biosciences Inc. Announces Completion of Clinical Portion of Overdose Protection Trial PF614-MPAR-101-Part A

Consensus revenue estimates fall by 33%

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Price target increased to US$240

High number of new directors

Ensysce Biosciences Announces FDA Guidance on the Clinical Development Pathway for Pf614

Ensysce Biosciences Announces Positive Topline Results of Clinical Study Evaluating Human Abuse Potential of Intranasal Administration of PF614, A TAAP Abuse-Deterrent Oxycodone Extended-Release Product

Ensysce Biosciences, Inc. Announces First Subjects Dosed in Second Human Abuse Potential Study

Ensysce Biosciences Announces Initiation of Second Human Abuse Potential Study, Being Conducted by DVCR

Ensysce Biosciences, Inc. Announces Chief Medical Officer Changes

Ensysce Biosciences and Quotient Sciences Announce A Partnership on the Development and Clinical Testing of Ensysce's PF614-MPAR, A Novel Opioid Designed to Prevent Abuse and Overdose

Consensus forecasts updated

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Ensysce Biosciences, Inc. announced that it has received $8 million in funding

Independent Chairman of the Board notifies of intention to sell stock

Ensysce Biosciences secures $8M convertible note financing

Ensysce Biosciences, Inc. Appoints William Chang as Director

Ensysce Biosciences, Inc. Receives Non-Compliance Letter from Nasdaq Related to Bid Price

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Ensysce Biosciences, Inc. Announces New Clinical Results from Trials PF614-102 and Pf614-MPAR-101

High number of new directors

Ensysce Biosciences, Inc., Annual General Meeting, Jun 23, 2022